Media ReleasesImugene Limited

View All Imugene Limited News


Imugene Enhances Portfolio with Compelling Oncolytic Virus

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California

  • FDA Investigational New Drug (IND) package
  • Worldwide, exclusive licence with long patent life
  • Phase 1 clinical trial anticipated to commence in 2020
  • Ex-Viralytics members part of project team for development of the oncolytic virus
Sydney, 15 July 2019 – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced that it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive license to a promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California.

For further information please download the attached PDF: Download this document